Cravatex Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 6:59 pm

Quick Insight

Cravatex Ltd's current share price of ₹475 seems overvalued with a P/E ratio of 25.5, indicating potentially inflated market expectations. The company's low ROE of 4.68% and ROCE of 6.57% suggest inefficiencies in capital utilization, impacting long-term shareholder value. However, its healthy OPM of 0.84% and strong reserves of ₹104 Cr provide a cushion for future growth. The low P/BV ratio of 0.83x implies undervaluation based on book value, offering a margin of safety for investors. With a high promoter holding of 75.00% and a comfortable interest coverage ratio of 20.39x, Cravatex Ltd demonstrates stability despite subdued profitability metrics, signaling potential for strategic improvements to unlock shareholder value.

Competitors of Cravatex Ltd

All Competitor Stocks of Cravatex Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:24 am

Below is a detailed analysis of the quarterly data for Cravatex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 60.52 Cr.. The value appears strong and on an upward trend. It has increased from 32.43 Cr. (Dec 2024) to 60.52 Cr., marking an increase of 28.09 Cr..
• For Expenses, as of Mar 2025, the value is 60.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.30 Cr. (Dec 2024) to 60.01 Cr., marking an increase of 25.71 Cr..
• For Operating Profit, as of Mar 2025, the value is 0.51 Cr.. The value appears strong and on an upward trend. It has increased from -1.87 Cr. (Dec 2024) to 0.51 Cr., marking an increase of 2.38 Cr..
• For OPM %, as of Mar 2025, the value is 0.84%. The value appears strong and on an upward trend. It has increased from -5.77% (Dec 2024) to 0.84%, marking an increase of 6.61%.
• For Other Income, as of Mar 2025, the value is 2.09 Cr.. The value appears to be declining and may need further review. It has decreased from 2.24 Cr. (Dec 2024) to 2.09 Cr., marking a decrease of 0.15 Cr..
• For Interest, as of Mar 2025, the value is 0.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.11 Cr. (Dec 2024) to 0.09 Cr., marking a decrease of 0.02 Cr..
• For Depreciation, as of Mar 2025, the value is 0.40 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.40 Cr..
• For Profit before tax, as of Mar 2025, the value is 2.11 Cr.. The value appears strong and on an upward trend. It has increased from -0.14 Cr. (Dec 2024) to 2.11 Cr., marking an increase of 2.25 Cr..
• For Tax %, as of Mar 2025, the value is 31.75%. The value appears to be increasing, which may not be favorable. It has increased from -278.57% (Dec 2024) to 31.75%, marking an increase of 310.32%.
• For Net Profit, as of Mar 2025, the value is 1.44 Cr.. The value appears strong and on an upward trend. It has increased from 0.25 Cr. (Dec 2024) to 1.44 Cr., marking an increase of 1.19 Cr..
• For EPS in Rs, as of Mar 2025, the value is 5.57. The value appears strong and on an upward trend. It has increased from 0.97 (Dec 2024) to 5.57, marking an increase of 4.60.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:01 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:30 pm

Below is a detailed analysis of the balance sheet data for Cravatex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
• For Reserves, as of Mar 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 104.00 Cr., marking an increase of 8.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 8.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 8.00 Cr..
• For Other Assets, as of Mar 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 108.00 Cr. (Mar 2024) to 116.00 Cr., marking an increase of 8.00 Cr..
• For Total Assets, as of Mar 2025, the value is 141.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 16.00 Cr..

Notably, the Reserves (104.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Cravatex Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
• For Diluted EPS (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
• For Cash EPS (Rs.), as of Mar 25, the value is 24.40. This value is within the healthy range. It has decreased from 25.97 (Mar 24) to 24.40, marking a decrease of 1.57.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 411.83. It has increased from 382.02 (Mar 24) to 411.83, marking an increase of 29.81.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 672.41. It has decreased from 784.12 (Mar 24) to 672.41, marking a decrease of 111.71.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 31.94. This value is within the healthy range. It has decreased from 32.66 (Mar 24) to 31.94, marking a decrease of 0.72.
• For PBIT / Share (Rs.), as of Mar 25, the value is 26.22. This value is within the healthy range. It has increased from 25.37 (Mar 24) to 26.22, marking an increase of 0.85.
• For PBT / Share (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.84 (Mar 24) to 24.66, marking an increase of 0.82.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.68. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 18.68.
• For PBDIT Margin (%), as of Mar 25, the value is 4.75. This value is below the healthy minimum of 10. It has increased from 4.16 (Mar 24) to 4.75, marking an increase of 0.59.
• For PBIT Margin (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from 3.23 (Mar 24) to 3.90, marking an increase of 0.67.
• For PBT Margin (%), as of Mar 25, the value is 3.66. This value is below the healthy minimum of 10. It has increased from 3.04 (Mar 24) to 3.66, marking an increase of 0.62.
• For Net Profit Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 5. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 8. It has increased from 2.38 (Mar 24) to 2.77, marking an increase of 0.39.
• For Return on Networth / Equity (%), as of Mar 25, the value is 4.53. This value is below the healthy minimum of 15. It has decreased from 4.89 (Mar 24) to 4.53, marking a decrease of 0.36.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.18. This value is below the healthy minimum of 10. It has decreased from 6.42 (Mar 24) to 6.18, marking a decrease of 0.24.
• For Return On Assets (%), as of Mar 25, the value is 3.43. This value is below the healthy minimum of 5. It has decreased from 3.87 (Mar 24) to 3.43, marking a decrease of 0.44.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.31. It has decreased from 1.55 (Mar 24) to 1.31, marking a decrease of 0.24.
• For Current Ratio (X), as of Mar 25, the value is 4.22. This value exceeds the healthy maximum of 3. It has decreased from 5.11 (Mar 24) to 4.22, marking a decrease of 0.89.
• For Quick Ratio (X), as of Mar 25, the value is 3.86. This value exceeds the healthy maximum of 2. It has decreased from 4.64 (Mar 24) to 3.86, marking a decrease of 0.78.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 20.39. This value is within the healthy range. It has decreased from 21.30 (Mar 24) to 20.39, marking a decrease of 0.91.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 13.18 (Mar 24) to 12.93, marking a decrease of 0.25.
• For Enterprise Value (Cr.), as of Mar 25, the value is 13.09. It has decreased from 36.92 (Mar 24) to 13.09, marking a decrease of 23.83.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 0.18 (Mar 24) to 0.07, marking a decrease of 0.11.
• For EV / EBITDA (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.59, marking a decrease of 2.78.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
• For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.14 (Mar 24) to 0.83, marking a decrease of 0.31.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.50, marking a decrease of 0.05.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness